Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Limited has informed the exchange regarding Financial Results for quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 27 Jul 2026, 03:31 PM IST · BSE ID: dd2c5d13-fc23-43a3-923c-36579b92872e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its Q1 financial results, showing Rs. 183.02 Crore total income and Rs. 30.45 Crore profit.
🤖 AI Summary
- Senores Pharmaceuticals Board approved Unaudited Consolidated and Standalone Financial Results for Q1 FY27.
- Consolidated Total Income stood at Rs. 183.02 Crore for the quarter ended June 30, 2026.
- Consolidated Net Profit after tax was Rs. 30.45 Crore for the quarter ended June 30, 2026.
- Ms. Anjali Shah, Assistant Vice President-Finance, appointed as Senior Management Personnel (SMP) effective July 27, 2026.
- M/s. Pankaj R. Shah and Associates, Statutory Auditors, issued Limited Review Reports on the financial results.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations
Rs. 180.21 Crore
Consolidated Other Income
Rs. 2.81 Crore
Consolidated Total Income
Rs. 183.02 Crore
29.48%
Consolidated Net Profit after tax
Rs. 30.45 Crore
43.77%
Basic Earnings per share
Rs. 6.61
43.70%
🏢 How This Affects the Company
The company reported its operational performance for Q1 FY27, with consolidated revenue from operations at Rs. 180.21 Crore.
Consolidated Net Profit after tax was Rs. 30.45 Crore for the quarter, impacting overall profitability for the period.
Appointment of Ms. Anjali Shah as Senior Management Personnel indicates an internal change in financial leadership structure.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results and management appointment filing.
👤
Who Is Affected
All shareholders are indirectly affected by the company's financial performance, specifically the increase in consolidated net profit to Rs. 30.45 Crore.
🔍
Management Signal
The Board's decision to appoint Ms. Anjali Shah as Senior Management Personnel signals an intent to strengthen the company's financial leadership team.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — observe sustained revenue and profit growth.
Update on IPO proceeds utilization for manufacturing facility and inorganic growth.
Further details on Ms. Anjali Shah's contributions in her new SMP role.
LOW RISK
The filing indicates positive financial results and no immediate new risks. Unutilized IPO funds require monitoring.
💡 Investor Takeaway
Senores Pharmaceuticals reported Q1 FY27 consolidated Total Income of Rs. 183.02 Crore, up from Rs. 141.35 Crore in Q1 FY26. Consolidated Net Profit after tax rose to Rs. 30.45 Crore from Rs. 21.18 Crore YoY.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Total Income for Q1 FY27 increased to Rs. 183.02 Crore compared to Rs. 141.35 Crore in Q1 FY26.
- Consolidated Net Profit after tax for Q1 FY27 increased to Rs. 30.45 Crore from Rs. 21.18 Crore in Q1 FY26.
⚠️ Concerns
- IPO proceeds utilization shows Rs. 100.02 Crore unutilized from the proposed Rs. 107.00 Crore for manufacturing facility setup.
- A balance of Rs. 0.28 Crore remains unutilized from the proposed Rs. 161.91 Crore for inorganic growth and strategic initiatives.
📅 Company Track Record
Senores Pharmaceuticals was incorporated in 2017 and recently listed with an IPO on December 30, 2024. Prior filings indicate FY26 Total Income up 65% to Rs. 664 Crore and PAT up 108%, showing strong past financial performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Senores Pharmaceuticals' consolidated net profit and total income for Q1 FY27?
Senores Pharmaceuticals reported a consolidated Net Profit after tax of Rs. 30.45 Crore and a consolidated Total Income of Rs. 183.02 Crore for the quarter ended June 30, 2026.
What was the year-on-year growth in Senores Pharmaceuticals' consolidated net profit for Q1 FY27?
The consolidated Net Profit after tax for Q1 FY27 was Rs. 30.45 Crore, a 43.77% increase from Rs. 21.18 Crore in the quarter ended June 30, 2025.
Who was appointed as Senior Management Personnel at Senores Pharmaceuticals?
Ms. Anjali Shah, Assistant Vice President-Finance, was appointed as Senior Management Personnel (SMP) of Senores Pharmaceuticals, effective July 27, 2026.
What is the status of IPO proceeds utilization for Senores Pharmaceuticals' manufacturing facility?
Out of the proposed Rs. 107.00 Crore for the Atlanta Manufacturing Facility, Rs. 6.98 Crore has been utilized as of June 30, 2026, leaving Rs. 100.02 Crore unutilized.
Questions based on this BSE filing only. For information purposes.